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Abstract 
Background: Type 2 Diabetes (T2D) is associated with dyslipidemia and chronic low-grade 
inflammation, which greatly increases the risk of cardiovascular disease (CVD) in this 
population.  Hyperlipidemia and inflammation in the postprandial state substantially contribute 
to atherosclerosis development and CVD risk, and have shown to be exacerbated by high-fat 
meals. Dietary cocoa is a rich source of flavanols that is associated with favorable effects on 
cardiovascular health, such as improvements in the lipid profile and chronic inflammation, in 
non-diabetic adults. 
Objective: To conduct a secondary data analysis using unpublished data from a previously 
conducted clinical study to determine whether acute cocoa supplementation reduces postprandial 
metabolic stress, through improvements in serum markers of lipid metabolism and inflammation, 
in obese T2D adults after a high-fat fast-food-style meal. 
Methods: Adults with T2D [n = 18; age (mean ± SE): 56±3y; BMI (kg/m2): 35.3±2.0; 14 
women; 4 men] were randomly assigned to receive cocoa beverage (960 mg total polyphenols; 
480 mg flavanols) or flavanol-free placebo with a high-fat fast-food-style breakfast [766kcal, 
50g fat (59% energy)] in a crossover trial. After an overnight fast, participants consumed the 
breakfast with cocoa or placebo, and blood sample collection [serum apoB, apoA1, NEFA, IL-
1β, IL-6, and IL-18] was conducted at fasting, 1, 2, 4, and 6 h postprandial time points. 
Results: Cocoa significantly decreased serum IL-18 levels at the 1, 4, and 6-h postprandial time 
points compared to placebo (p < 0.001), but had no effects on serum apoB, apoA1, NEFA, IL-
1β, or IL-6 levels. 
Conclusion: Cocoa may play a protective role against the development and progression of CVD 
through selective anti-inflammatory effects on postprandial IL-18. 
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Chapter 1: Introduction 
More than 30 million Americans currently suffer from Type 2 Diabetes (T2D), with 
greater than 1.5 million new cases arising each year (American Diabetes Association [ADA], 
2017). Diabetes greatly increases an individual’s risk of developing cardiovascular disease 
(CVD), the leading cause of death in the United States and worldwide (ADA, 2017). Increasing 
evidence suggests that hyperlipidemia and inflammation during the postprandial (post-feeding) 
state influences the development and progression of atherosclerosis, adversely affecting CVD 
risk.  Serum lipids and inflammatory biomarkers considered to be predictive of CVD risk are 
often elevated in T2D, and may be exacerbated in the postprandial state following the ingestion 
of a high-fat meal (Lopez-Miranda, Williams, & Lairon, 2007; Perez-Martinez et al., 2016; 
Tomkin & Owens, 2017). Diets with high polyphenol content have shown to have favorable 
effects on human health and may limit the incidence of disease associated with inflammation and 
metabolic stress, such and T2D and CVD (Aprotosoaie et al., 2016). Cocoa is an especially rich 
dietary source of flavanols, a subclass of polyphenols, and several previous studies suggest cocoa 
flavanols have anti-diabetic and anti-atherogenic effects (Ramos, Martin, & Goya, 2017). 
However, randomized controlled trials observing the effects of cocoa flavanols on postprandial 
metabolism are extremely limited. Therefore, the purpose of this study is to examine the effects 
of cocoa powder consumption on selected markers of postprandial lipid metabolism and 
inflammation following a high-fat fast-food-style meal in T2D participants. 
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Alternate Hypotheses: 
1. Acute cocoa beverage consumption will significantly decrease postprandial apoB and
NEFA, and increase postprandial apoA1 serum concentrations following a high-fat fast-
food-style meal compared to placebo.
2. Acute cocoa beverage consumption will significantly decrease postprandial serum levels
of IL-1β, IL-6, and IL-18 following a high-fat fast-food-style meal compared to placebo.
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Chapter 2: Review of the Literature 
Prevalence of Diabetes and Cardiovascular Disease 
Type 2 Diabetes (T2D) is a metabolic disease characterized by chronic hyperglycemia due to 
both insulin resistance (IR) and insulin insufficiency. The pathogenesis of T2D is believed to be 
multifactorial, with poor nutrition, physical inactivity, and obesity (especially in the intra-
abdominal region) being the most strongly associated risk factors. T2D accounts for 90-95% of 
all adult diabetes diagnoses and is currently the 7th leading cause of death in the United States, 
killing approximately 1.5 million people per year. The number of mortalities stemming  
from T2D is expected to double by year 2030 (ADA, 2017). 
Diabetes greatly increases an individual’s risk of developing CVD, the leading cause of death in 
the United States and worldwide. Diabetic adults are 2-4 times more likely to develop and die 
prematurely from CVD compared to individuals without diabetes (Khavandi et al., 2017; Wu & 
Parhofer, 2014). CVD currently accounts for approximately 1/3 of all US deaths, with coronary 
artery disease and stroke being responsible for more than 60% of these mortalities (American 
Heart Association [AHA], 2017). It is predicted that by year 2030, greater than 23.6 million 
people worldwide will die from CVD each year (World Health Organization [WHO], 2017). 
Risk factors strongly associated with atherosclerotic cardiovascular disease (ASCVD) include 
obesity, excess central adiposity, poor dietary intakes, physical inactivity, chronic 
hyperglycemia, hypertension and dyslipidemia, all of which are often observed in individuals 
with T2D (AHA, 2017; WHO 2017).  
Pathophysiology of Type 2 Diabetes 
Glucose homeostasis is maintained and regulated through a negative feedback loop, primarily 
involving the hormones insulin and glucagon. When blood glucose levels are elevated, insulin is 
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secreted by the beta cells of the pancreas to stimulate the uptake of glucose by the insulin-
sensitive tissues, such as the hepatic, skeletal muscle, and adipose tissues. Glucose uptake occurs 
due to insulin’s effect on the intracellular insulin-dependent GLUT4 glucose transporters. Insulin 
signals the translocation of the GLUT4 transporters from the interior of the cell to the cellular 
membrane in order to transport glucose from the blood into the cell. Once cellular glucose uptake 
has occurred, the glucose can then be oxidized and used for energy, converted to and stored as 
glycogen in either the skeletal muscle or liver (glycogenesis), or converted into triglyceride and 
stored in the adipose tissue (lipogenesis). Blood glucose levels then return to normal and insulin 
levels are suppressed. Glucagon has the opposing effect of insulin and acts to increase blood 
glucose levels when they have declined, as they do in times of fasting. When blood glucose 
levels are low, glucagon is secreted by the alpha cells of the pancreas, stimulating the 
endogenous production of glucose (gluconeogenesis) through the breakdown of glycogen 
(glycogenolysis) and/or adipose tissue (lipolysis). If necessary, gluconeogenesis can also occur 
through the breakdown of body proteins into amino acids that can be converted to glucose. The 
process of gluconeogenesis restores blood glucose levels and glucagon is suppressed.  
Insulin Resistance and Insulin Insufficiency 
All forms of diabetes share the common characteristic of chronic hyperglycemia stemming from 
defects in insulin action, insulin production, or both (Nelms, 2016). The manifestation of T2D 
requires the presence of both insulin resistance— the hypo-responsiveness of the insulin-
sensitive tissues to insulin, and insulin insufficiency—the progressively deficient production of 
insulin (Kahn, Cooper, & Del Prato, 2014).  The development and clinical presentation of T2D is 
generally gradual and insidious, with insulin resistance often occurring for several years prior to 
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the clinical onset of the disease. Clinical presentation of T2D is largely associated with a decline 
in insulin production (Nelms, 2016).  
When alterations in glucose metabolism initially arise, the beta cells are often functioning 
properly but the insulin-sensitive tissues have started to become insensitive to the insulin being 
secreted. It is thought that this desensitization to insulin is, in part, caused by insufficient insulin 
receptors on the normally insulin-sensitive target cells, preventing or decreasing the intracellular 
signaling and translocation of the GLUT4 receptors to the cell membrane (Nelms, 2016). This 
results in decreased glucose uptake by the insulin-sensitive tissues and leads to an increase in 
insulin output by the beta cells to try to compensate for the rising blood glucose levels. Over 
time, the beta cells become incapable of keeping up with the chronically elevated blood glucose 
levels and no longer produce enough insulin to maintain normal blood glucose concentrations, 
resulting in impaired glucose tolerance. The progressive deterioration in beta cell function, and 
reduction in the number of β-cells, further elevates plasma glucose levels and contributes to the 
evolution from impaired glucose tolerance to T2D (Kahn, 2014).  
Obesity, especially intra-abdominal adiposity, is strongly associated with the development of 
T2D (Kahn, 2014).  As of year 2014, greater than 90% of those with T2D were overweight or 
obese and greater than 60% were obese (ADA, 2017). Environmental factors shown to heavily 
contribute to the development of obesity and central adiposity include physical inactivity, 
excessive energy intake, and nutrient composition of the diet—specifically, diets high in 
saturated fats and fructose, and low in fiber and omega 3 polyunsaturated fatty acids (Kahn, 
2014).  
Diabetic Dyslipidemia 
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Dyslipidemia, characterized by elevated fasting and postprandial plasma concentrations of 
triglyceride (TG) and small, dense low-density lipoprotein (sdLDL) particles, along with low 
plasma levels of high-density lipoprotein cholesterol (HDL-C), is commonly observed in 
individuals with T2D (Khavandi et al., 2017). These lipid abnormalities are believed to largely 
contribute to the markedly increased risk of ASCVD exerted on those with T2D (Wu & Parhofer, 
2014). Lipoproteins transport lipids throughout the body for uptake and use by the cells of the 
periphery, largely the muscle and adipose tissues. Chylomicrons (CM) and very low-density 
lipoproteins (VLDL) are both rich in TG, with the main differences between them being that CM 
transport exogenous sources of lipid and VLDL transport endogenous sources of lipid. Lipolysis 
of both CM- and VLDL-TG is dependent on the action of lipoprotein lipase (LPL). Once LPL 
has hydrolyzed the majority of the CM-TG, the remaining remnant particles are cleared from 
circulation by the liver. The lipolysis of VLDL-TG results in smaller, denser IDL particles, 
which are then further hydrolyzed and converted into cholesterol-rich LDL particles. The main 
function of LDL is to deliver cholesterol to the peripheral cells. In contrast, HDL are involved in 
reverse cholesterol transport, which serves to transport excess cholesterol from the cells back to 
the liver to be recycled or excreted (Feng et al., 2017; Khavandi et al., 2017).  
Apolipoproteins are proteins found on the surface of all lipoproteins and are both structural and 
functional components of the lipoprotein. Two important functional roles of apolipoproteins 
involve the activation of enzymatic reactions and allowing for the binding of the lipoprotein to 
its designated receptor on the surface of the peripheral cells (Khavandi et al., 2017). 
Apolipoprotein-B (apoB) is the main protein component of CM, VLDL, IDL, and LDL particles 
and promotes the uptake of TG and cholesterol into the peripheral tissues and liver (Hem, Kumar 
& Tamang, 2014). Apolipoprotein A-1 (apoA1) is the main protein component of HDL particles 
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and facilitates the transfer of cholesterol from the tissues into HDL particles. Plasma apoB levels 
are positively correlated and plasma apoA1 are inversely correlated with IR and T2D. Since all 
apoB-lipoproteins are considered atherogenic and apoA1-containing HDL particles are 
considered anti-atherogenic, elevated serum levels of apoB and low serum levels of apoA1 are 
associated with an increased risk of ASCVD (Hem, Kumar & Tamang, 2014).  
ApoB 
High serum LDL-C concentration is considered an independent risk factor of ASCVD and the 
lowering of LDL-C levels is a primary goal of medical treatment to prevent ASCVD and 
subsequent major cardiac events. However, focusing exclusively on LDL-C levels has shown to 
be less than optimal at reducing the risk of ASCVD and major cardiovascular events. It is 
estimated that 50% of all patients with ASCVD have LDL-C levels within or even below the 
recommended range of 70-100 mg/dL, yet still experience a major CV event (Ramjee, Sperling, 
& Jacobson, 2011; Varvel et al., 2015).  This residual risk is due, at least in part, to the 
discordance between serum concentrations of LDL-C and atherogenic apoB-containing 
lipoproteins.  This discordance is related to the considerable variability of cholesterol levels that 
can exist within the LDL particle (LDL-P). Having a predominant amount of cholesterol-
depleted, sdLDL particles results in a lower concentration of LDL-C but a greater concentration 
of apoB particles in the blood. Since apoB is a constituent of all atherogenic lipoproteins, the 
total serum apoB concentration represents the total number of atherogenic particles in the blood. 
It is estimated that 34% of the population should be considered high-risk for ASCVD due to IR 
and elevated serum apoB concentrations, yet are overlooked as a result of having optimal LDL-C 
levels (Varvel et al., 2015). Therefore, the assessment of serum apoB levels may be more 
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effective in identifying ASCVD risk and preventing CV events in those with T2D (Harper & 
Jacobson, 2010; Varvel et al., 2015; Wilkins et al., 2016). 
ApoA1 
A low level of serum HDL-C (<40mg/dL for men and <50mg/dL for women) is considered an 
independent risk factor for ASCVD, whereas a high level of serum HDL-C (>60mg/dL) is 
considered to be cardio-protective.  Reverse cholesterol transport (RCT), along with the anti-
inflammatory, anti-oxidant, and anti-thrombotic properties of HDL, constitute its anti-
atherogenic effects. However, the measurement of HDL-C quantity is not always indicative of 
HDL-P functionality (Eren, Yilmaz, & Aydin, 2012; Florvall, Basu, & Larsson, 2006; Sharif et 
al., 2016). Despite having optimal HDL-C levels, some individuals still develop ASCVD and 
experience a major CV event. It is estimated that almost 50% of those who experience a major 
CV event have both LDL-C and HDL-C levels within an optimal range. This supports the notion 
that not all HDL protects against the development of ASCVD and its related morbidity and 
mortality (Eren et al., 2012).  In fact, Sharif et al (2016) found that in patients with T2D, elevated 
levels of HDL-C were associated with an increased risk of CV events and mortality when LDL-
C levels were less than 80 mg/dL, indicating that higher levels of HDL-C are not always 
advantageous (Sharif et al, 2016). Also, a study in mice revealed that dysfunctional hepatic 
HDL-P receptors lead to high levels of serum HDL-C but also to the rapid development of 
extreme atherosclerosis (Eren et al, 2012).  Results from these and other studies suggest that 
HDL-P functionality may be more indicative of ASCVD risk than HDL-C quantity (Eren et al., 
2012; Florvall et al., 2006; Sharif et al., 2016). ApoA1 largely influences HDL-P functionality 
and recent evidence implies that apoA1 may be a stronger biomarker than HDL-C in predicting 
CV-related morbidity and mortality (Eren et al., 2012; Florvall et al., 2006; McQueen et al.,
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2008; Sharif et al., 2016). ApoA1 normally accounts for approximately 70% of all HDL-P 
proteins and is thought to be widely responsible for the anti-atherogenic properties of HDL (Eren 
et al., 2012). Modification of the apoA1 composition of the HDL-P leads to a dysfunctional 
HDL-P with a decreased ability to remove excess cholesterol from both the peripheral cells and 
the cholesterol-rich macrophages within the arterial wall. Modified and dysfunctional HDL-P 
transforms from anti-inflammatory, cardio-protective to pro-inflammatory, atherogenic 
molecules. Chronic systemic inflammation and oxidative stress, dyslipidemia and glycation of 
apoA1, all often seen in T2D, are positively associated with the modification of apoA1 and the 
resulting dysfunction of HDL-P.  
ApoB/ApoA1 Ratio 
The ratio of apoB to apoA1 (apoB/apoA1) represents the balance between total atherogenic 
apoB-containing lipoprotein particles and anti-atherogenic HDL-P in the blood. Many studies 
have shown the apoB/apoA1 ratio to be a stronger predictor of ASCVD compared to traditional 
lipid markers or its individual constituent apolipoprotein values (Kaneva et al., 2015; Krintus et 
al., n.d.; Lu et al., 2011; Tamang et al., 2014; Upadhyay, 2015). In fact, some studies have shown 
the apoB/apoA1 ratio to be the only serum lipid value with the ability to differentiate between 
patients with and without coronary artery disease (CAD), even when these patients present with 
normal serum lipid concentrations (Kaneva et al., 2015). A study by Tamang et al (2014) 
evaluated the predictive power of the apoB/apoA1 ratio in determining CVD risk by comparing 
several different lipid parameters between adults with and without CVD (Tamang et al., 2014). 
Significant results were observed between the CVD and non-CVD groups for apoB (107 vs. 91 
mg/dL) and apoB/apoA1 ratio (1.00 vs. 0.84), but not for apoA1 or LDL-C. (Tamang et al, 
2014). Krintus et al (n.d.) compared apolipoprotein concentrations and the apoB/apoA1 ratio to 
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conventional lipid markers in adult women with and without acute coronary syndromes (ACS). 
ApoB/apoA1 ratio values were significantly higher (0.62 vs. 0.5) and apoA1 values were 
significantly lower (132 vs. 155 mg/dL) in ACS patients compared to controls, though there were 
no significant differences between LDL-C or apoB concentrations. Additionally, 83% of the 
healthy control subjects in this study had an apoB/apoA1 ratio value indicative of low-risk for 
CVD, whereas 55% of the ACS patients had an apoB/apoA1 ratio value that indicated moderate 
to high risk of CVD (Krintas et al., n.d.). 
Type 2 Diabetes, Alterations in Postprandial Lipid Metabolism, and NEFA 
There has been a large amount of research conducted examining the relationship between lipid 
metabolism and the development of ASCVD. Serum lipid measurements are often performed in 
the fasting state, which mostly reflects endogenous lipid and lipoprotein metabolism. However, 
many with obesity and T2D spend a substantial amount of time in the fed state due to the daily 
consumption of three or more meals, sometimes along with snacks. Abnormalities in 
postprandial lipid metabolism are commonly seen in individuals with T2D, even when fasting 
lipid levels are within normal range. Given that most with T2D are in the postprandial state for a 
large portion of their day and that postprandial dyslipidemia is commonly observed, the 
assessment of postprandial lipid metabolism in this population is highly relevant to predicting 
ASCVD risk (Annuzi et al., 2008; Khavandi, 2017; Lopez-Miranda et al., 2007; Perez-Martinez 
et al., 2016). Several studies have shown that chronic over-nutrition, diets high in saturated fat 
and/or sucrose, and diets low in fiber, lead to an increase in the postprandial production and 
decreased circulatory clearance of apoB-particles in T2D (Annuzi 2008; Boren & Williams, 
2016; Khavandi, 2017; Lopez-Miranda et al., 2007; Perez-Martinez et al, 2016). Elevated 
postprandial apoB-particle production and secretion is positively associated with IR, and is often 
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seen in obese, insulin-resistant individuals with and without T2D (Annuzi, 2008; Khavandi, 
2017). One possible mechanism to explain this response in those with IR is the suppression of 
insulin’s anti-lipolytic effect in the adipose tissue. Insulin levels are typically elevated in the 
early postprandial state, suppressing both adipose tissue lipolysis and hepatic apoB-particle 
production. In IR and T2D this action of insulin is altered, resulting in heightened concentrations 
of non-esterified fatty acids (NEFA) from adipose tissue and hepatic-derived apoB-particles 
(Lopez-Miranda et al., 2007; Khavandi, 2017). Insulin resistance also inhibits apoB-particle 
lipolysis by lipoprotein lipase (LPL), prolonging the circulatory residence time of these particles. 
The prolonged circulatory time and delayed clearance of these particles from circulation results 
in the formation of both small, dense LDL particles and TG-rich HDL particles. TG-rich HDL 
particles are smaller than cholesterol-rich HDL particles and are more readily catabolized, 
resulting in the low plasma HDL-C concentrations commonly observed in T2D. Meals 
containing between 30-50 grams of fat are usually required to witness exaggerated elevations in 
postprandial TG-rich apoB-particle production, and it is not uncommon for meals in westernized 
societies to contain, on average, 20-70 grams of fat per meal. Consumption of consecutive high-
fat meals further contributes to postprandial dyslipidemia, resulting in TG-rich apoB-particles 
levels remaining well above baseline for up to 8 hours following each meal (Lopez-Miranda et 
al., 2007).  
Type 2 Diabetes is also associated with elevated fasting and postprandial NEFA levels. NEFA 
are derived from the lipolysis of both adipocyte and apoB-lipoprotein TG, and serum levels are 
typically elevated in the fasted state and suppressed in the postprandial state due to the anti-
lipolytic effect of insulin. However, NEFA levels are often elevated in the fed state following a 
high-fat meal (Frayn, 2005; Karpe, Dickmann & Frayn, 2011). In the fasted state, adipose tissue 
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lipolysis is almost entirely responsible for serum NEFA concentrations but, after a high-fat meal, 
spillover fatty acids from the hydrolysis of CM-TG can account for up to 40-50% of postprandial 
serum NEFA concentrations (Karpe et al., 2011). NEFA that are not taken up by the tissues 
“spillover” into the blood and are shunted to the liver.  Elevated levels of plasma NEFA and the 
subsequent increase in hepatic TG derived from NEFA heighten hepatic apoB-lipoprotein 
production and secretion, further exacerbating the postprandial dyslipidemia occurring in T2D 
(Frayn, 1998; Khavandi et al., 2017; Lambert & Parks, 2012). Elevated NEFA levels are also 
frequently observed non-diabetic, IR states, likely due to the reduced sensitivity of the adipose 
tissue to insulin and a failure of insulin to suppress lipolysis in the postprandial period (Karpe et 
al., 2011). While it is not yet clear whether elevated NEFA concentrations are independent risk 
factors for ASCVD, they have shown to be positively associated with many established risk 
factors, such as IR, VLDL and TG levels, blood pressure, and endothelial dysfunction (Frayn, 
2005; Karpe et al., 2011; Xiong, Xu & Huang, 2015). Xiong et al (2015) examined the 
relationship between serum NEFA and CVD mortality in elderly men with chronic kidney 
disease (CKD). Though they did not find a relationship between serum NEFA and renal function, 
they did reveal that serum NEFA were independent predictors of CVD-related mortality in 
elderly men with CKD (Xiong et al., 2015). 
Clinical Importance of Serum Lipids and Apolipoproteins 
ApoB 
The American Diabetes Association/American College of Cardiology (ADA/ACC) position 
statement suggests an apoB goal of <80 mg/dL for those considered highest-risk and <90 mg/dL 
for those considered high-risk for ASCVD (Harper & Jacobson, 2010). Slightly different 
recommendations exist, with The American Association of Clinical Chemistry (AACC) 
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recommending an apoB goal of <80 mg/dL for high-risk patients and the Canadian 
Cardiovascular Society suggesting an apoB goal of <80 mg/dL for high- and moderate-risk 
patients (Ramjee et al., 2011). Mayo Clinic Medical Laboratories considers plasma apoB levels 
less than 90mg/dL desirable, 110-119 mg/dL borderline high, 120-139mg/dL high, and 
≥140mg/dL very high risk for CAD. They also suggest a therapeutic goal of <90 mg/dL for 
individuals with moderate to high risk of developing CAD and <80 mg/dL for those at very high 
risk of CAD (Mayo Clinic Medical Laboratories, n.d.). Results from a study performed by Adeli 
et al (2015), which sought to create comprehensive reference values representative of healthy 
Canadians aged 3-79 years, found median serum concentrations of apoB to be 90 mg/dL (Adeli 
et al., 2015). Results from other recent clinical trials support the use of an apoB goal of <80 
mg/dL in high-risk patients for reducing the risk of major CV events and ASCVD-related 
mortality (Harper & Jacobson, 2010; Ramjee et al., 2011).  
ApoAl 
According to Mayo Clinic – Mayo Medical Laboratories, optimal serum concentrations of 
apoA1 are those greater than 120mg/dL for males and 140mg/dL for females (Mayo Clinic 
Medical Laboratories, n.d.). Serum concentrations falling below these values are considered 
high-risk for CVD development. Results from a study performed by Adeli et al (2015), which 
sought to create comprehensive reference values representative of healthy Canadians aged 3-79 
years, found median serum concentrations of apoA1 in both males and females aged 40-79 years 
to be above the previously mentioned reference values stated from Mayo Clinic Medical 
Laboratories (Adeli et al., 2015). 210 samples of serum apoA1 were collected for both males and 
females aged 40-79 years. Serum concentrations of apoA1 among this population ranged from 
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120-200mg/dL in males, with the median serum concentration being 140 mg/dL, and 110-230
mg/dL in females, with the median serum concentration being 160 mg/dL (Adeli et al., 2015).  
ApoB/ApoA1 Ratio 
An apoB/apoA1 ratio value of greater than 0.9 for males and 0.8 for females is widely accepted 
to be an indication of high-risk for ASCVD development (Kaneva et al., 2015; Krintus et al., 
n.d.; Mayo Clinic Medical Laboratories, n.d.; Tamang et al., 2014). An apoB/apoA1 ratio value
of 0.6-0.8 indicates a moderate risk and a value of less than 0.6 represents a low risk of CAD 
development and related CV events in women (Mayo Clinic Medical Laboratories, n.d.; Krintus 
et al., n.d.). In men, apoB/apoA1 values between 0.7-0.9 represent a moderate risk and a value 
below 0.7 represents a low risk of CAD and related CV events (Mayo Clinic Medical 
Laboratories, n.d.; Krintus et al., n.d.). A study by Kaneva et al (2015) examining the 
relationship of the apoB/apoA1 ratio with other lipid parameters in seemingly healthy, middle-
aged men with normolipidemia found that 81% of the study population had an apoB/apoA1 ratio 
value of less than 0.9 (median value of 0.48), supporting the apoB/apoA1 reference values 
previously mentioned (Kaneva et al., 2015).  
NEFA 
While it is generally agreed upon that increased NEFA levels, especially in the postprandial 
period, are positively associated with IR, obesity, and CVD risk, suggested reference values vary 
within the literature and between laboratories. Frayn (2005) and Karpe et al (2015) propose 
NEFA concentrations in the range of 0.1-1.0 mmol/L and 0.3-0.6 mmol/L, respectively, to be 
normal and of low-risk in disease development (Frayn, 2005; Karpe et al., 2015). Mayo Clinic 
Medical Laboratories suggests a reference range of 0.0-0.72 mmol/L (Mayo Clinic Medical 
Laboratories, n.d.).   
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Type 2 diabetes, Inflammation, and Relation to ASCVD 
Type 2 Diabetes is considered a chronic, low-grade inflammatory state, evidenced by the over-
production of several different pro-inflammatory cytokines, such as interleukin 1 beta (IL-1β), 
interleukin 6 (IL-6), and interleukin 18 (IL-18). Chronically heightened production of pro-
inflammatory cytokines brings about an inflammatory environment within the vasculature and is 
considered to be the foundation of atherosclerosis development and progression (Peiro et al., 
2017). Meals high in saturated fat, sucrose, and/or total energy content appear to be the main 
triggers of the postprandial inflammatory response, with an exaggerated response seen in obese 
and T2D individuals (Telle-Hansen et al., 2017). Since these pro-inflammatory molecules are 
thought to directly contribute to the development of CVD, they present as useful biomarkers to 
help determine CVD risk. Elevated levels of circulating pro-inflammatory cytokines, such as IL-
1β, IL-6, and IL-18 are positively associated with T2D, obesity, and ASCVD, and their 
concentrations may be exacerbated by the ingestion of high-fat meals (Esposito et al., 2003; 
Fogarty et al., 2014). 
Serum Inflammatory Markers of Interest  
IL-6 
IL-6 is a pro-inflammatory cytokine largely produced and secreted by the adipose tissue, 
endothelial cells, and activated leukocytes. IL-6 plays a critical role in the acute-phase 
inflammatory response and is believed to directly contribute to atherosclerosis development and 
progression (Ridker, 2016). Elevated levels of IL-6 are commonly observed in obesity, IR and 
T2D, and are associated with a greater risk of both ASCVD and all-cause mortality (Derosa & 
Maffioli, 2016). It has been shown that each SD increase in log IL-6 results in a 25% greater risk 
of a major adverse cardiac event (Ridker, 2016). Fernandez-Real et al (2001) examined the 
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association between serum IL-6 concentrations, IR, and blood pressure in 228 healthy, non-
medicated obese subjects and found IL-6 levels to be positively associated with both fat mass 
and IR in non-smokers of both sexes, IR in male subjects, and blood pressure in female subjects 
(Fernandez-Real et al., 2001). Bastard et al (2000) compared serum IL-6 levels of obese diabetic 
women to both obese and lean non-diabetic women. This study discovered that the obese 
diabetic subjects had significantly higher IL-6 levels compared to both the obese non-diabetic 
subjects and lean controls, and that the obese non-diabetic subjects had significantly higher IL-6 
levels compared to lean controls (3.58 ± 0.51 vs. 2.78 ± 0.30 vs. 0.39 ± 0.06 pg/mL) (Bastard et 
al., 2000). This study also found IL-6 serum levels to be positively correlated with degree of 
obesity and IR, and after weight loss resulting from three weeks on a very low calorie diet, the 
non-diabetic obese subjects saw an increase in insulin sensitivity and a significant decrease is 
serum IL-6 levels (2.78 ± 0.3 vs. 2.32 ± 0.19 pg/mL) (Bastard et al., 2000). 
IL-1β 
IL-1β is a pro-inflammatory cytokine produced by monocytes and macrophages in the adipose 
tissue, pancreatic beta cells, and aortic endothelium. IL-1β is believed to heavily contribute to the 
initiation and progression of atherosclerosis through its potent ability to stimulate many 
secondary inflammatory mediators, such as IL-6, enhancing monocyte attraction and adhesion to 
the epithelium (Peiro et al., 2017; Ridker, 2016). The adhered monocytes release additional pro-
inflammatory cytokines, including IL-1β, resulting in further monocyte recruitment and adhesion 
to the area. Human islet cell studies have demonstrated an elevated production and secretion rate 
of IL-1β in a hyperglycemic environment, indicating IL-1β has a causal role in β-cell dysfunction 
and apoptosis, resulting in insufficient insulin production in T2D (Dinarello, Donath & 
Mandrup-Poulsen, 2010). Cholesterol crystals deposited within the arterial wall have also shown 
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to enhance IL-1β production, linking dyslipidemia to vascular inflammation and ASCVD 
(Ridker & Luscher, 2014). Because IL-1β is a potent driver of IL-6 and CRP production, both 
which have shown to be predictive of ASCVD and major CV event risk, its inhibition has 
become a promising therapeutic target to reduce inflammation, ASCVD, and CV event rates 
(Ridker, 2016). In fact, pharmacologic inhibition of IL-1β activity has shown to reduce 
circulating IL-6 and hsCRP levels by more than 50% and the incidence of major CV events by 
up to 14% in high-risk CVD patients (Ridker et al., 2017; Ridker & Luscher, 2014). Even though 
circulating IL-1β concentrations are typically low, and often times undetectable, they have 
shown to be up to five times greater in patients with various autoinflammatory diseases 
(Dinarello et al., 2010). 
IL-18 
IL-18 is a pro-inflammatory cytokine that is largely produced and secreted from visceral adipose 
tissue. Numerous animal models have established a causal role of IL-18 in the progression of 
atherosclerosis, primarily due to its initiation of other pro-inflammatory, atherogenic cytokines 
(Ballak et al, 2015; Landberg et al., 2011).  In humans, plasma levels of IL-18 are positively 
correlated with degree of IR and are often elevated in obese, T2D, and CAD patients (Ballak et 
al., 2015; Dezayee, 2011; Nakamura et al., 2015; Suchanek et al., 2005). Elevated levels of IL-18 
are associated with an increased risk of ASCVD in individuals with established T2D, and are 
considered to be a strong predictor of cardiovascular-related and all-cause mortality (Dezayee, 
2011; Suchanek et al., 2005). Nakamura et al (2015) examined if serum IL-18 levels could be 
used to predict atherosclerosis in T2D patients. This study found that IL-18 levels were 
significantly higher in those with T2D compared to age-matched healthy controls (179 ± 62 vs. 
121 ± 55 pg/mL) and were positively correlated with various parameters of atherosclerosis 
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(Nakamura et al., 2015).  Suchanek et al (2005) compared serum IL-18 levels in CAD patients 
with and without T2D to healthy age and BMI-matched controls. Serum concentrations were 
significantly greater in CAD subjects with T2D compared to CAD subjects without T2D and 
compared to healthy controls (mean of 500 vs. 430 vs. 250 pg/mL) (Suchanek et al., 2005).   
Clinical Importance of Serum Inflammatory Markers of Interest  
IL-6 
Mayo Clinic Medical Laboratories suggests IL-6 serum values be less than or equal to 1.8 pg/mL 
in healthy individuals (Mayo Clinic Medical Laboratories, n.d.). Some studies measuring IL-6 
levels in healthy subjects have found mean serum concentrations within this range (Bastard et al., 
2000; Davison et al., 2012). However, a study by Kleiner et al (2013), which sought to create 
reference guidelines for several serum cytokines in healthy individuals, found the mean IL-6 
serum concentration of healthy adults (n=35) to be approximately 11 pg/mL (5-16 pg/mL) 
(Kleiner et al., 2013). Several other studies have also found mean serum concentrations of 
healthy controls to be well above the reference value stated by Mayo Clinic Medical 
Laboratories. Measurement of plasma IL-6 levels in 228 healthy, obese subjects revealed a mean 
concentration of 6.4 pg/mL (1.0-13.1 pg/mL) in men and 5.8 pg/mL (1.8-14 pg/mL) in women 
(Fernandez-Real et al., 2001). In healthy, non-obese controls, Kokkonen et al (2010) and Sarria 
et al (2014) found baseline IL-6 levels to be 4.6 pg/mL (1.1-10.8 pg/mL) and 4.3 pg/mL (.50), 
respectively (Kokkonen et al., 2010; Sarria et al., 2014). 
IL-1β 
The expression of IL-1β is limited in healthy individuals and is often low or below the level of 
detection even in patients with inflammatory disease (Dinarello et al., 2010; Peiro et al, 2017). 
Mayo Clinic Medical Laboratories suggests IL-1β serum values be less than 1.0 pg/mL in 
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healthy persons (Mayo Medical Laboratories, n.d.). In the before mentioned study by Kleiner et 
al (2013), serum IL-1β concentrations were below the limit of detection, which was 3.2 pg/mL, 
in all healthy sample subjects (total subjects, n = 72; subjects ≥ 18 years of age, n =35) (Kleiner 
et al., 2013). Spranger et al (2003) also noted undetectable IL-1β serum levels in 62% of study 
patients (n=565), with a mean of 0.57 ± 0.93 in case subjects (developed T2D within 2-3 years of 
follow-up) and 0.47 ± 0.79 in healthy, age and sex-matched control subjects (Spranger et al., 
2003). However, other studies examining IL-1β serum values in healthy control subjects found 
slightly elevated mean baseline concentrations of 2.6 (0.8-3.9) pg/mL and 3.43 (0.32) pg/mL 
(Kokkonen et al., 2010; Sarria et al., 2014).  
IL-18 
To our knowledge, there are no reference values established for IL-18. However, Kleiner et al 
(2013) found that all healthy adult subjects (n=35) had serum IL-18 concentrations of less than 
200 pg/mL, with the mean being below 100 pg/mL (Kleiner et al., 2013). Other studies 
comparing serum IL-18 levels of T2D or CAD patients to healthy control subjects found mean 
concentrations of 121-284 pg/mL in the healthy study participants (Landberg et al., 2011; 
Nakamura et al., 2015; Suchanek et al., 2005).    
Dietary Polyphenols 
Polyphenols are a structural category of organic chemicals characterized by the existence of 
multiple phenolic units. Several thousand polyphenols have been identified and many of them 
are found in plant foods, such as fruits, vegetables, tea, coffee, and cocoa beans (Manach et al., 
2004). Polyphenols are classified into subgroups according to their chemical structure. The five 
main classes of polyphenols are: Flavonoids, Phenolic Acids, Stilbenes, Lignans, and Others. 
There is strong evidence to support the notion that diets with a high polyphenol content have 
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favorable effects on human health and may limit the incidence of disease associated with 
inflammatory and oxidative stress, such as T2D and ASCVD  (Aprotosoaie et al., 2016). Possible 
biological effects of polyphenols associated with a reduction in chronic disease include: 
Correction of hyperglycemia due to the augmentation of insulin secretion and sensitivity; 
Improvement of dyslipidemia by the lowering of LDL-C, total cholesterol and TG, and elevation 
of HDL-C concentrations; Amelioration of endothelial dysfunction through the enhancement of 
flow-mediated dilation (FMD), nitric oxide (NO) levels; Reduction of blood pressure; and the 
lessening of inflammatory and oxidative stress due to the inhibition of LDL oxidation and 
reduced levels of pro-inflammatory cytokines (Merone & McDermott, 2017; Tome-Carneiro & 
Visioli, 2016). Suggested mechanisms of action related to the positive effects of polyphenol-rich 
diets are the ability of polyphenols to modulate cell-signaling pathways and act as antioxidants to 
defend against oxidative stress (Manach et al., 2004).  
Cocoa 
Flavonoids are the largest subclass of dietary polyphenols and are predominantly found in cocoa, 
coffee, tea, red wine, and many fruits. Cocoa is an especially rich source of flavonoids, having 
the largest flavanol (a subclass of flavonoids) content by weight of all foods, with flavanols 
compromising ~12-18% of raw, dried cocoa beans (Aprotosoaie et al., 2016; Grassi, Desideri & 
Ferri, 2013). Dietary sources of cocoa generally containing the largest amount of flavanols are 
ground cocoa and dark chocolate (Aprotosoaie et al., 2016). A large body of research suggests 
that cocoa flavanols may have anti-diabetic and anti-atherogenic effects that alleviate the 
hallmarks of T2D, such as hyperglycemia, dyslipidemia, chronic inflammation, hypertension, 
and endothelium dysfunction, therefore reducing the risk of ASCVD (Grassi et al., 2013; Ramos 
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et al., 2017). The most abundant flavanol found in cocoa and cocoa-derived products is (-)-
epicatechin (EC) and EC can likely be credited for the beneficial metabolic effects of cocoa.  
A number of systematic reviews and meta-analyses examining the effects of cocoa on human 
health have been conducted over the past 10 years (Aprotosoaie et al., 2016; Ellinger & Stehle, 
2016; Ludovici et al., 2017; Ramos et al., 2017; Tome-Carneiro & Visioli, 2016). The large 
majority of recent meta-analyses generated demonstrate that moderate cocoa consumption, 
defined as up to 6oz. of flavanol-rich cocoa products per week, has a beneficial effect on IR, 
serum lipids, and systemic inflammation (Ramos et al., 2017).  These positive effects may in-
turn reduce the risk of ASCVD development. Also, several epidemiological studies have shown 
an inverse relationship between consumption of flavanol-rich chocolate and risk of premature 
cardiovascular and all-cause mortality (Ludovici et al., 2017).  
Anti-diabetic effects of cocoa 
In-vitro, experimental animal, human intervention, and epidemiological studies conducted over 
the past decade provide strong support for the anti-diabetic effects of cocoa flavanols. The most 
common anti-diabetic actions of cocoa supported by in-vitro studies include enhanced levels of 
insulin secretion, a decreased degree of IR, and mitigation of abnormal lipid values (Ramos et 
al., 2017). Attenuation of β-cell damage and death, and heighten levels of β-cell replication, have 
been credited for the enhanced insulin secretion observed. Improvements in IR were attributed to 
heightened levels of glucose transporters (GLUT2 & GLUT4) and key proteins involved in the 
insulin-signaling pathway, resulting in improved glucose uptake by both liver and skeletal 
muscle cells, and decreased glucose production in hepatic cells. Cocoa also exhibited an 
insulinomimetic effect in adipocytes, decreasing the rate of FA synthesis and increasing the rate 
of FA oxidation, alleviating lipid accumulation (Ramos et al., 2017). Most studies using 
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experimental animal models to investigate the effects of cocoa flavanols on hyperglycemia and 
T2D reveal promising results. In fact, dietary cocoa supplementation has shown to be one of the 
most compelling nutritional methods used over the last decade in order to prevent and treat T2D 
(and decrease the risk of CVD) in experimental rats and mice (Ramos et al., 2017). Minimized 
deterioration and enhanced function of β-cells, decreased production of pro-inflammatory 
cytokines, heightened insulin sensitivity, and improved lipid metabolism are among the 
favorable effects of cocoa on T2D observed in experimental rat models (Ramos et al., 2017). 
Also, cocoa supplementation has not demonstrated any toxicity in experimental animals, even in 
studies lasting longer than three months (Ramos et al., 2017). Short-term consumption of 
flavanol-rich cocoa products in humans has also shown to ameliorate pathologies contributing to 
T2D, such as IR, pancreatic β-cell dysfunction, and insulin insufficiency (Grassi et al., 2013; 
Ramos et al., 2017).  
Effects of cocoa on serum lipids  
Both animal and human studies have indicated that flavanol-rich cocoa and cocoa products 
impose a beneficial effect on serum lipid profiles (Aprotosoaie et al., 2016; Basu et al., 2015; 
Cordero-Herrara et al., 2015; Gutierrez-Salmean et al., 2014; Neufingerl et al., 2013; Parsaeyan 
et al., 2014; Rostami et al., 2015; Tokede, Gaziano & Djousse, 2011). The majority of the RCTs 
conducted to examine the effects of cocoa or cocoa flavanols on serum lipids have used non-
diabetic participants, with only two reporting this relationship in subjects with T2D (Basu et al., 
2015; Rostami et al., 2015) and studies observing the effects of cocoa flavanols on 
apolipoprotein metabolism are scarce (Lee et al., 2017; Neufingerl et al., 2013; Rostami et al., 
2015). Basu et al (2015) examined the effect of 20 grams cocoa powder (480 grams of total 
flavanols) served along with a high-fat fast-food-style breakfast on postprandial serum lipids and 
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other markers of metabolic stress. This study concluded that HDL-C levels were significantly 
higher during the 6-hour postprandial period after the cocoa intervention compared to placebo 
(p=0.011), however there was no treatment effect found for LDL-C or TG levels (Basu et al., 
2015). Rostami (2015) conducted a RCT to examine the effects of cocoa polyphenols on serum 
apoA1 and apoB concentrations in hypertensive patients with T2D. This study found that daily 
consumption of 25 grams dark chocolate (450mg total flavonoids) for eight weeks resulted in a 
significant decrease from baseline in apoB (-4.46 ± 9.44 pg/mL, p = .012) and increase from 
baseline in apoA1 (+4.56 ± 12.36 pg/mL, p = .045), whereas no significant differences were 
observed in the placebo group (Rostami et al., 2015). However, even though the change from 
baseline was statistically significant for these variables following the dark chocolate intervention, 
the effect size was small. Lee et al (2017) examined the effect of regular consumption of sixty-
one grams of dark chocolate and cocoa (CHOC), and sixty-one grams of dark chocolate and 
cocoa combined with forty-three grams almonds (CHOC + ALD), on apoB and apoA1 
concentrations in healthy overweight and obese participants. Each treatment period lasted for 
four weeks and diets were controlled for the entire duration of the study (isocaloric, weight 
maintenance diets). In this study, neither the CHOC nor the CHOC + ALD treatment 
significantly influenced apoA1 levels compared to the control diet, but apoB concentrations and 
the apoB/apoA1 ratio were significantly lower in the CHOC + ALD compared to the control diet 
(apoB: 101.9 ± 2.4 vs. 107.5 ± 2.4 mg/dL, p=0.01; apoB/apoA1: 0.7 vs. 0.8, p=0.02) (Lee et al., 
2017).  Neufingerl et al. (2013) also performed a RCT to examine the effects of cocoa and 
theobromine on serum lipoproteins and apolipoproteins. Healthy participants were given one 
beverage per day for four weeks containing 6 grams cocoa powder (150 mg theobromine, 325 
mg flavonoids), pure theobromine (850 mg), cocoa plus theobromine (1000 mg theobromine, 
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325 mg flavonoids), or placebo. Results showed that pure theobromine significantly increased 
serum HDL-C (6.2 ± 1.6 mg/dL, p<0.0001) and apoA1 (11 ± 2 mg/dL, p<0.0001), and decreased 
LDL-C (-7.0 ± 3.1 mg/dL, p=0.016) and apoB (-5.0 ± 2.0 mg/dL, p=0.002) from baseline 
following the four week intervention, whereas cocoa powder alone did not have a significant 
effect on these variables (Neufingerl, 2013).  
Effects of cocoa on inflammation  
Cocoa flavanols have shown powerful anti-inflammatory and antioxidant properties in-vitro. 
Antioxidant and anti-inflammatory functions that have been exhibited in-vitro are inhibited 
platelet activation, diminished LDL oxidation, repressed synthesis and expression of pro-
inflammatory cytokines, and increased production of anti-inflammatory factors (Aprotosoaie et 
al., 2016; Ellinger & Stehle, 2016; Parsaeyan et al., 2014). In high-fat-fed obese C57BL/6J mice, 
supplementation with 8% cocoa powder for 10 weeks reduced IL-6 production by 30.4% 
compared to high-fat-fed mice not receiving cocoa supplementation (Gu, Yu & Lambert, 2014). 
Human studies examining the effects of cocoa consumption on serum pro-inflammatory 
cytokines, especially IL-6, IL-1β, and IL-18, in a diabetic population are extremely limited 
(Ellinger & Stehle, 2016; Goya et al., 2016). A RCT in subjects with T2D and hyperlipidemia 
indicated that consumption of 10 g of cocoa powder, twice per day for six weeks, reduced serum 
IL-6 levels by 32% (2.5 ± 0.9 vs. 1.7 ± 0.7 pg/ml) (Parsaeyan et al., 2014). This same study also 
revealed a significant improvement in total cholesterol (16.6% decrease; 246mg/dl to 205mg/dl), 
LDL-C (17.54% decrease; 135mg/dl to 111mg/dl) and TG (13.3% decrease; 226mg/dl to 195 
mg/dl) levels after the six weeks of dietary cocoa supplementation, which was significantly less 
than the reductions seen in the control group (total cholesterol 5%, LDL-C 4%, and TG 3%). 
Another RCT conducted by Stote et al. (2012) investigated the effect of cocoa on various serum 
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markers of inflammation following an OGTT in obese individuals with impaired glucose 
tolerance. This study found that daily consumption of two moderate-flavanol content cocoa 
drinks (400 mg flavanols) for five days significantly decreased IL-6 concentrations following the 
OGTT compared to the low-flavanol (180 mg flavanols) group (2.1 vs. 2.8 pg/mL)  (Stote et al., 
2012). To our knowledge, there have not been any human intervention studies conducted looking 
at the effect of cocoa ingestion on IL-1β in T2D: however, Sarria et al (2014) examined this 
effect in healthy and moderately hypercholesterolemic subjects and found that consumption of 
two, fifteen-gram servings of cocoa powder per day (416 mg polyphenols) for four weeks 
significantly reduced IL-1β concentrations in the moderately hypercholesterolemic subjects 
compared to placebo (-0.95 vs. -0.33 pg/mL, p=0.011) (Sarria et al., 2014). This study also found 
that 4 weeks of cocoa supplementation significantly increased HDL-C and decreased blood 
glucose levels (Sarria et al., 2014).  
To our awareness, there have not been any published studies examining the effect of cocoa 
consumption on serum IL-18 levels, however, there have been studies conducted exploring this 
effect using other high-polyphenol foods or diets. An observational study by Landberg et al 
(2011) reported that higher intake of total flavonoids and flavonoids from citrus fruits were 
inversely correlated with IL-18 concentrations in healthy US women (Landberg et al., 2011). In 
this study, mean IL-18 concentrations in the greatest total flavonoid intake quintile were 8% 
lower than those in the lowest total flavonoid intake quintile (55 vs. 276 pg/mL). Among the 
foods assessed in this study, tea, apples and citrus fruits were the greatest contributors to total 
flavonoid intake (Landberg et al., 2011). Another study in healthy adults examined the effect of 
sweet bing cherries on IL-18 levels and found that consumption of 280 grams of sweet bing 
cherries per day for twenty-eight days reduced IL-18 levels by 8.1% (Kelley et al., 2013).  In 
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adult patients with Metabolic Syndrome, two years of a Mediterranean-style diet (high in dietary 
polyphenols, fiber, and unsaturated fatty acids) significantly reduced IL-18 levels compared to 
the control group (11% vs. 2% reduction, p=0.3) (Esposito et al., 2014). Another study 
examining the effect of a Mediterranean-style diet on IL-18 concentrations found that three years 
of this style diet significantly lowered IL-18 levels (-10.5% from baseline) compared to the 
control diet in elderly, white males considered to be at high-risk of developing CVD  (p=0.012) 
(Troseid et al., 2009). In contrast to these results, Marfella et al (2006) found no significant 
change in IL-18 levels after twelve months on a Mediterranean-style diet in T2D adults who had 
recently experienced their first myocardial infarction; however, this same style diet in 
conjunction with moderate red wine consumption at meals significantly lowered IL-18 levels 
compared to the non-wine group (mean change of -61.7±5.1 vs. -28.2±3.8 pg/mL) (Marfella et 
al., 2006). Lastly, in obese, T2D adults, an eight-week high-fiber diet that also contained a large 
amount of coffee (≥5 cups/d) resulted in a modestly significant decrease in IL-18 levels 
compared to the low-fiber, no coffee control group (p<0.05) (Nowotny et al., 2014).  
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Chapter 3: Methodology  	
This thesis study is a secondary data analysis of unpublished data from a previously conducted 
clinical study by Basu et al. (2015), which examined the effects of cocoa on serum lipoproteins, 
endothelial function, and inflammation following a high-fat fast-food-style meal in a T2D 
population. The study design has been previously published and is stated below (Basu et al., 
2015). Approval for this secondary data analysis was obtained from the Institutional Review 
Board of the University of Nevada, Las Vegas.  
Participants. The Institutional Review Boards of the Oklahoma University Health Sciences 
Center and the Oklahoma State University approved the original study protocol. Written 
informed consent was acquired from all enrolled participants. All study procedures were 
administered at the Harold Hamm Diabetes Center at the Oklahoma University Health Sciences 
Center. Four men and fourteen women with established, stable T2D for a minimum of five years, 
not on insulin therapy, and with a waist circumference of  >89 cm for women or >102 cm for 
men were screened for inclusion in the study. T2D eligibility was confirmed according to the 
guidelines of the American Diabetes Association (ADA, 2017). Potential participants were 
excluded if they were <21 y of age; presented with preexisting conditions, such as cancer or 
coronary heart disease; were anemic or had abnormal liver, renal, or thyroid function on the basis 
of screening examinations; were consuming antioxidants or fish oil supplements on a regular 
basis; were current smokers or regular consumers of alcohol (no more than 1–2 drinks/wk.); 
were currently enrolled in a weight loss program; or were pregnant or lactating. Presence of 
CVD risk factors, such as elevated blood pressure or serum lipids, did not inhibit participation in 
the study. Each participant’s regular oral medications were continued throughout the duration of 
the study.  
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Study design. Volunteers completed a randomized, double blind, crossover study in which they 
made two separate visits to the study site. They arrived to the site in a fasted state (10–12 h) and 
each visit lasted 6–7 h. The two study days were separated by a 1-wk washout phase. On each 
study day, blood draws were performed at baseline (fasting state) and then again at 30 (0.5h), 60 
(1h), 120 (2h), 240 (4h), and 360min (6h) postprandial time points, starting from the time of 
completion of the provided meal and beverage. After the fasting blood draw, participants 
consumed a high fat fast-food style breakfast with either the cocoa or placebo beverage. The 
meal was prepared at the clinic and consumption of the test meal by participants was supervised. 
Participants were instructed to refrain from alcohol and caffeine for 24 h prior to each study visit, 
and foods or dietary supplements with high polyphenol content for 48 h prior to each study visit. 
With the exception of the previously stated instructions, participants were asked to maintain their 
usual diet, medications, and lifestyle for the entire duration of the study. Three-day food records 
(two weekdays and one weekend day) were collected at baseline, prior to the start of the study, 
and nutrient and food group intakes were analyzed with Nutritionist Pro version 3.2 (Axxya 
Systems).  
Interventions. The nutritional composition of the cocoa and placebo powder has been previously 
published (Basu et al., 2015). The total polyphenol and flavanol content per serving was 
substantially higher in the cocoa powder compared to the flavanol-free placebo powder. The total 
polyphenol content was determined by the Folin-Ciocalteu assay as described by Singleton et al. 
(Singleton & Rossi, 1965), and the total flavanol content was determined by the 4-
dimethylaminocinnamaldehyde assay as described by Payne et al. (Payne et al., 2010). Besides 
the cocoa, the test powder contained the following ingredients: sunflower oil, corn syrup solids, 
and ≤2% food additives (carrageenan, vanillin, salt, sodium caseinate, aspartame, dipotassium 
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phosphate, monoglycerides, diglycerides, acesulfame potassium, soy lecithin, and silicon 
dioxide). The composition of the placebo powder mix was similar to that of the cocoa mix, 
except the cocoa was substituted with milk protein isolate. The fast-food–style breakfast meal 
consisted of two scrambled eggs (no added fat), hash brown potatoes (70 g), two buttermilk 
biscuits, butter (15 g), and a sausage patty (57 g), and provided a total of 766 kcal, 50 g total fat 
(25 g saturated fats, 12 g monounsaturated fats, 13 g polyunsaturated fats; 59% energy), 50 g 
carbohydrates (26% energy), 30 g proteins (16% energy), 465 mg cholesterol, and 2.4 g dietary 
fiber. All ingredients for the test meals were purchased from a local grocery store and prepared 
in the metabolic kitchen of the clinic each morning on both testing days. The cocoa and placebo 
mixes were reconstituted in warm water and were provided to the participants in closed lid cups 
along with the breakfast meal for supervised consumption.  
Anthropometrics. On each day of the trial, after an overnight fast and before blood sampling, 
body weight was measured on a calibrated scale, height was measured with the use of a 
stadiometer, and waist circumference (60.05 cm) was measured at the superior iliac crest.  
Biochemical variables. Freshly drawn blood samples were sent to the Oklahoma University 
Medical Center Laboratory for analysis of serum lipids (apoB, apoA1, and NEFA) and 
inflammatory markers (IL-1β, IL-6, and IL-18). Analyses for the serum lipids were conducted 
with the use of automated diagnostic equipment (Abbott Architect Instruments) by enzymatic 
colorimetric methods that used commercially available kits according to manufacturer’s 
protocols. Analyses for the inflammatory markers were conducted with the use of R&D Human 
Elisa kits according to the manufacturer’s protocol.  
Statistical analysis. For each outcome, change from baseline (i.e., the fasting, pre-intervention 
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time point) was calculated for each postprandial time point. Differences between intervention 
and placebo were analyzed with the use of paired t-tests. Data analyses were conducted with the 
use of IBM SPSS Statistics version 23.0 (IBM Corp.). Results corresponding to P < 0.05 are 
described as significant for the purposes of discussion. For this crossover design, between-
intervention comparisons were performed at each time point with the use of generalized 
estimating equation analyses to account for the repeated measures in the same individual. 
Between-intervention comparisons across all time points, that is, for the entire 6-h time period, 
were performed with the use of generalized estimating equation analyses (with results indicated 
as overall P).  
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Chapter 4: Results 	
Baseline Characteristics. Out of twenty-six participants assessed for eligibility, eight were 
excluded due to not meeting inclusion criteria and 18 were enrolled and completed the study. All 
participants were obese (BMI > 30kg/m2) with clinically diagnosed T2D. The majority of 
participants were taking oral hypoglycemic agents (83%) and antihypertensive agents (84%), but 
none were on insulin therapy. At baseline, participants had hyperglycemia (FBG > 126mg/dL), 
elevated blood pressure and LDL-C, and hsCRP levels considered at high risk for CVD 
(>3.0g/L). Baseline dietary analyses indicated that participant’s usual diets were high in fat (37% 
total kcals) and low in fruits and vegetables. Baseline characteristics are presented in Table 2. 
Postprandial Serum Lipids. Serum apoA1, apoB and NEFA concentrations, and the apoB:apoA1 
ratio were not significantly different over the 6-h postprandial period following cocoa 
intervention compared with placebo. There was a significant effect of time on NEFA levels, with 
NEFA concentrations being significantly lower at the 1, 2, and 4-h postprandial time points 
compared to baseline (p<0.001) (Table 3).  
Postprandial Inflammatory Markers. Serum IL-6 and IL-1β concentrations were not significantly 
different over the 6-h postprandial period following cocoa intervention compared to placebo. 
However, serum IL-18 levels were significantly lower at the 1, 4, and 6-h postprandial time 
points following cocoa intervention compared to placebo (p<0.001) (Table 4, Figure 1).  
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TABLE 1 Composition of cocoa and placebo powder administered 
 
 Cocoa Placebo 
Serving Size, g 20 12 
Energy, kcal 67 66 
Fat, g 4.7 5.0 
Protein, g 2.7 1.1 
Carbohydrates, g 9.6 4.0 
Carbohydrate: Protein 3.6:1 3.6:1 
Fiber, g 4.4 0.1 
Total Polyphenols, mg 960 110 
Total Flavanols, mg 480 <0.1 
Proanthocyanidins (PAC) 1-10, mg 201 <0.001 
Epicatechins, mg 40 0 
Catechins, mg 18 0 
Theobromine, mg 220 0 
Caffeine, mg 21 0 
 
Source: The Hershey Company (Hershey, PA, USA) 
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TABLE 2.   Baseline characteristics of the study participants 
Variable Value 
N 18 
Age, y 56±3.2 
Gender, M/F 4/14 
Weight, kg 100±12 
BMI, kg/m2 35.3±2.0 
Waist Circumference, inches 45±1.8 
Serum glucose, mg/dL 136±16 
Serum insulin, mU/L 14.8±2.6 
Insulin resistance (HOMA-IR) 3.5±0.9 
Serum HbA1c, % 8.2±0.6 
Serum total cholesterol, mg/dL 188±11 
Serum LDL cholesterol, mg/dL 112±11 
Serum HDL cholesterol, mg/dL 46±2.5 
Serum LDL:HDL 2.54±0.24 
Serum triglycerides, mg/dL 140±13 
Serum hsCRP, mg/L 5.3±1.2 
Systolic blood pressure, mm Hg 144±5.5 
Diastolic blood pressure, mm Hg 85±3.0 
Small artery elasticity index, mL/mmHg x 100 5.6±3.6 
Large artery elasticity index, mL/mmHg x 10 17±7.4 
Medication/supplement use n (%) 
Insulin 0 (0) 
Oral hypoglycemic agents 15 (83) 
Statins/fibrates 5 (28) 
CCBs 3 (17) 
ACEIs/ARBs 10 (56) 
Diuretics 2 (11) 
Aspirin 6 (33) 
Multivitamins/minerals 6 (33) 
Botanical supplements 2 (11) 
Macronutrient and food intake 
Energy, kcal/d 2216±198 
Carbohydrates, g/d 263±38 
Total fats, g/d 92±8 
Protein, g/d 94±9 
Fiber, g/d 30±9 
Fruit servings, g/d 144±52 
Vegetable servings, g/d 160±35 
Mean ± SEMs for continuous variables; ACEIs/ARBs: angiotensin converting enzyme 
inhibitors/ angiotensin receptor blockers; CCBs: calcium channel blockers; HOMA-IR: 
homeostasis model assessment of insulin resistance; hsCRP: high sensitivity C-Reactive Protein. 
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TABLE 3: Serum apolipoprotein and NEFA values during the cocoa and placebo interventions. 
Variable Fasting 1hr 2hr 4hr 6hr P-value
Apo-B 
(mg/dL) 
Placebo 
Cocoa 
96 ± 4.0 
96 ± 5.0 
93 ± 5.0 
94 ± 5.0 
95 ± 4.0 
97 ± 5.0 
97 ± 5.0 
94 ± 5.0 
98 ± 4.0 
100 ± 5.0 
Interaction: 0.58 
Time: 0.70 
Treatment: 0.57 
Apo-A1 
(mg/dL) 
Placebo 
Cocoa 
155 ± 6.0 
158 ± 8.0 
167 ± 8.0 
153 ± 7.0 
153 ± 8.0 
155 ± 6.0 
162 ± 9.0 
167 ± 8.0 
164 ± 8.0 
166 ± 8.0 
Interaction: 0.26 
Time: 0.06 
Treatment: 0.97 
NEFA 
(mg/dL) 
Placebo 
Cocoa 
0.64 ± .05 
0.62 ± .04 
0.42 ± .05 
0.49 ± .04 
0.36 ± .03 
0.44 ± .04 
0.45 ± .03 
0.51 ± .05 
0.71 ± .06 
0.65 ± .05 
Interaction: 0.07 
Time:  <0.001*   
Treatment: 0.70  
ApoB/ApoA1 
Ratio 
Placebo 
Cocoa 
0.63 ± .03 
0.63 ± .04 
0.57 ± .04 
0.63 ± .04 
0.66 ± .04 
0.64 ± .04 
0.63 ± .05 
0.59 ± .04 
0.62 ± .04 
0.63 ± .05 
Interaction: 0.51 
Time: 0.48   
Treatment: 0.92  
Data represented as mean ± SEM; Apo-B: apolipoprotein-B; Apo-A1: apolipoprotein-A1; 
NEFA: non-esterified fatty acids; ApoB/ApoA1 Ratio: ratio of apolipoprotein-B to 
apolipoprotein-A1; *Significant effect of time on NEFA levels over 6-h postprandial period in 
both treatment groups, P < 0.001 
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TABLE 4: Serum IL-6, IL-1β, and IL-18 values during the cocoa and placebo interventions.  
 
Variable  Fasting 1hr 2hr 4hr 6hr P-value 
 
 
IL-6, pg/mL 
 
         
Placebo 
 
Cocoa 
 
 
6 ± 2.0 
 
3 ± 0.5 
 
 
4 ± 1.0 
 
5 ± 0.7 
 
 
7 ± 2.0 
 
6 ± 2.0 
 
 
5 ± 1.0 
 
3 ± 0.6 
 
 
5 ± 2.0 
 
4 ± 1.0 
 
Interaction: 0.51	
 
Time: 0.06 
 
Treatment: 0.39 
 
 
IL-1β, 
pg/mL 
 
Placebo 
 
Cocoa  
 
 
 
3 ± 1.0 
 
3 ± 0.4 
 
 
 
2 ± 0.4 
 
5 ± 2.0 
 
 
 
3 ± 1.0 
 
3 ± 0.4 
 
 
 
3 ± 1.0 
 
6 ± 1.0 
 
 
 
4 ± 0.6 
 
4 ± 0.4 
 
 
Interaction: 0.77 
 
Time: 0.55 
 
Treatment: 0.15 
 
 
IL-18, 
pg/mL 
 
Placebo 
 
Cocoa  
 
 
 
303 ± 13 
 
300 ± 12 
 
 
 
302 ± 11 
 
279 ± 11 
 
 
 
290 ± 12 
 
286 ± 12 
 
 
 
325 ± 13 
 
267 ± 9 
 
 
 
339 ± 15 
 
250 ± 9 
 
 
Interaction: <0.001** 
 
Time: 0.45 
 
Treatment: 0.001* 
 
 
 
Data represented as mean ± SEM; IL-6: interleukin-6; IL-1β: interleukin-1-beta; IL-18: 
interleukin-18; *significant effect of cocoa intervention on IL-18 levels throughout 6-hour 
postprandial period, P < 0.001; **significant difference between cocoa and placebo interventions 
on IL-18 levels throughout 6-h postprandial period, P < 0.001 
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Figure 1: Serum IL-18 values over the 6-hour postprandial period following cocoa and placebo 
interventions	
Data represented as mean ± SEM; IL-18: interleukin-18; IL-18 serum levels in pg/mL; 
significant effect of cocoa intervention on IL-18 levels compared to placebo at 1h (p=0.03), 4h 
(p=0.001), and 6h (p<0.001) postprandial time points 
235	
250	
265	
280	
295	
310	
325	
340	
355	
Fasting	 1	hour	 2	hours	 4	hours	 6	hours	
Cocoa	 Placebo	
p	=	0.03	 p	=	0.001	 p	<	.001	
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Chapter 5: Discussion & Conclusion 
Diabetic dyslipidemia and alterations in postprandial lipid metabolism have shown to 
contribute to the development and progression of ASCVD. Epidemiological evidence suggests 
that the consumption of flavanol-rich cocoa products is associated with a reduced risk of 
ASCVD, and several previously conducted clinical studies have shown cocoa to ameliorate lipid 
profiles through improvements in HDL-C, LDL-C, and/or TG. The results of our study did not 
reveal a significant effect of cocoa on postprandial apoA1 or apoB levels, or on the apoB/apoA1 
ratio following a high-fat fast-food-style breakfast in T2D participants. These results are in 
agreement with two previously conducted short-term, regular-consumption studies examining the 
effect of cocoa on serum apoB and apoA1 concentrations in healthy lean (Neufingerl et al, 2013) 
and healthy overweight subjects (Lee et al, 2017). However, a study by Rostami et al (2015) 
showed that short-term, regular consumption of flavanol-rich dark chocolate significantly 
decreased apoB and increased apoA1 levels from baseline in participants with T2D and 
hypertension. Discrepancies between study results may be explained by differences in study 
duration (acute bolus vs. eight weeks regular consumption), study design (crossover vs. parallel), 
treatment dose (dark chocolate vs. cocoa powder of varying flavanol content), and sample size. 
Also, studies have shown serum levels of apoB to be higher and apoA1 to be lower in men 
compared to similar aged women in both healthy and CVD participants (Frondelius et al., 2017; 
Sharma et al., 2013). It is possible that differences in post-prandial apoB and apoA1 metabolism, 
and the response of these apolipoproteins to cocoa, exist between men and women. Thus, having 
a sample population with only four male participants (22% of total sample) may have affected 
our findings. It is recommended that future studies explore whether sex differences exist for 
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postprandial apoB and apoA1 metabolism and their response to flavanol-rich dietary 
interventions.  
 Our postprandial study did not show a significant effect of cocoa on plasma NEFA levels 
compared to placebo. This result is consistent with another postprandial study that examined the 
effect of flavanol-rich cocoa on NEFA concentrations following an oral fat load (Westphal & 
Luley, 2010). According to a study conducted by Jackson et al (2005), NEFA levels peak at the 
7-hour postprandial time point following a high-fat mixed meal, thus it is possible that we would 
have seen a significant effect of cocoa on plasma NEFA levels had our study been of longer 
duration. Our study did show a significant effect of time (p<0.001) on postprandial NEFA levels. 
As expected, NEFA levels were suppressed in the early postprandial phase, being the lowest at 
the 2-hour postprandial time point, and then showed a rise in levels back to baseline by the 6-
hour postprandial time point. A similar effect of time was seen in other postprandial studies 
examining the effect of a high-fat mixed meal on plasma NEFA levels in healthy adults (Jackson 
et al., 2005; Teng et al., 2015). 
Flavanol-rich cocoa products have shown to exhibit substantial anti-inflammatory effects 
in animal and in-vitro studies, but results of human studies have been conflicting. The results of 
our study did not show any significant effects of cocoa powder on postprandial IL-1β or IL-6 
levels in T2D participants following ingestion of a high-fat fast-food-style meal. These findings 
are consistent with previously conducted short-term, regular consumption studies in healthy 
(Mathur et al., 2002), overweight and obese (West et al., 2014), hypertensive (Muniyappa et al., 
2008), and T2D (Monagas et al., 2009) participants.  However, in contrast to our findings, short-
term, regular cocoa consumption has shown to significantly reduce IL-1β concentrations 
compared to placebo in moderately hypercholesterolemic subjects (Sarria et al., 2014) and IL-6 
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concentrations in obese (Stote et al., 2012) and hyperlipidemic T2D (Parsaeyan et al., 2014) 
subjects. Inconsistencies between study results may be elucidated by variances in study duration 
(acute bolus vs. daily, short-term consumption), study design (crossover vs. parallel), population 
studied, treatment dose (amount/composition of cocoa powder treatment used), and sample size.  
 On the other hand, the results of our study showed cocoa powder significantly reduced 
IL-18 levels compared to placebo at one, four, and six hours following a high-fat fast-food-style 
breakfast in T2D participants. At the six-hour postprandial time point, serum IL-18 levels had 
decreased from baseline by 17% following the cocoa intervention, whereas they had increased by 
12% following the placebo trial. The effect size observed (d = -1.7) is considered large, implying 
cocoa had a substantial, meaningful effect on serum IL-18 levels in this study. While reported 
studies on cocoa have not reported effects on IL-18, our results are in agreement with other 
studies examining how IL-18 concentrations are affected by various high-polyphenol foods or 
diets in healthy (Kelley et al., 2013; Landberg et al., 2011), metabolic syndrome (Esposito et al., 
2014), T2D (Marfella et al., 2009; Nowotny et al., 2014), and high CVD risk (Troseid et al., 
2009) participants. Mechanisms of action responsible for the reductions of IL-18 by high-
polyphenol diets or foods have yet to be elucidated. IL-18 is first expressed as an inactive 
precursor, pro-IL-18, which is activated to mature IL-18 by caspase-1 (Dinarello et al., 2013; 
Trøseid, Seljeflot, & Arnesen, 2010). Circulating levels of active IL-18 are neutralized by IL-18 
binding protein (IL-18BP) in healthy adult humans and animals (Dinarello et al., 2013). The 
binding of IL-18 to IL-18BP inhibits the pro-inflammatory intracellular signaling capabilities of 
IL-18. An imbalance between free IL-18 and IL-18BP results in elevated levels of circulating 
free IL-18 (and it’s pro-inflammatory effects) and this imbalance has shown to worsen as disease 
severity escalates (Trøseid et al., 2010). The reduction of circulating IL-18 levels observed in our 
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study and in other studies using high-polyphenol dietary interventions may be due to the ability 
of these interventions to enhance the production or prevent the inhibition of IL-18BP expression. 
Future studies examining the mechanism of action responsible for the reduction of IL-18 levels 
by polyphenol-rich dietary interventions are recommended.  
Our study has some limitations that should be considered when analyzing the results. The 
relatively small sample size in our exploratory study may have affected the statistical 
significance in certain inflammatory variables, though our study had adequate power for lipid 
and lipoprotein variables. Other limitations of this study were the absence of a non-diabetic 
control group or a low-fat test meal for comparisons; non-standardization of the diet during the 
study, especially the evening meal the night prior to study days; and the lack of assessment for 
habitual consumption of cocoa and other flavanol-rich foods prior to the study. Lastly, this was 
an acute intervention study and it is possible that a single dose of flavanol-rich cocoa powder 
may not exert an effect on all of the outcome variables assessed.  
In conclusion, our study showed that ingestion of cocoa powder along with a high-fat 
fast-food-style breakfast significantly decreased postprandial serum IL-18 levels but had no 
significant effects on postprandial apoB, apoA1, NEFA, IL-6 or IL-1β levels compared to 
placebo in a T2D population. Further studies examining the acute and long-term effects of 
flavanol-rich cocoa consumption on serum IL-18 are recommended to confirm our findings and 
determine whether cocoa plays a protective role against the development and progression of 
ASCVD.  
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